Tags

Type your tag names separated by a space and hit enter

Similar outcomes of allogeneic hematopoietic cell transplantation from unrelated donor and umbilical cord blood vs. sibling donor for pediatric acute myeloid leukemia: Multicenter experience in China.
Pediatr Transplant. 2015 Jun; 19(4):413-21.PT

Abstract

In a multicenter study, we have conducted a retrospective study on 73 pediatric AML patients who were primary refractory or in greater than CR1 and investigated MSD (or MMSD) (n = 20), URD (n = 23), and UCB (n = 30) HCT between January 1998 and October 2009. The median day to neutrophil engraftment was similar in all groups. The median day to platelet engraftment was longer in the UCB group. The number of HLA mismatch was higher in the UCB group (p = 0.034); however, the cumulative incidence of grade III-IV aGVHD was not different among all groups (p = 0.125); furthermore, cGVHD was lower in the UCB group (p = 0.078). The risk of relapse did not differ among all groups (RR = 1.28, p = 0.125), but the patients of MSD (or MMSD) grafts had a trend of higher risk recurrence. Sixty-two patients survived with a median follow-up of 58.2 months. Five-yr LFS was 73.1%, 59.8%, and 59.6% for URD, UCB, and MSD (or MMDS), respectively (p = 0.426). Five-yr LFS in CR1 was 68.9%, with a significantly better result compared to 41.7% in CR2 (p = 0.025). Our comparisons suggest that pediatric AML patients receiving UCB had a higher early TRM, a lower cGVHD rate, and a similar long-term survival. The outcome of URD and UCB is comparable to that of a suitable sibling for pediatric AML.

Authors+Show Affiliations

Department of Pediatrics, Navy General Hospital, Beijing, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study

Language

eng

PubMed ID

25903451

Citation

Tang, Xiangfeng, et al. "Similar Outcomes of Allogeneic Hematopoietic Cell Transplantation From Unrelated Donor and Umbilical Cord Blood Vs. Sibling Donor for Pediatric Acute Myeloid Leukemia: Multicenter Experience in China." Pediatric Transplantation, vol. 19, no. 4, 2015, pp. 413-21.
Tang X, Chen J, Fang J, et al. Similar outcomes of allogeneic hematopoietic cell transplantation from unrelated donor and umbilical cord blood vs. sibling donor for pediatric acute myeloid leukemia: Multicenter experience in China. Pediatr Transplant. 2015;19(4):413-21.
Tang, X., Chen, J., Fang, J., Sun, X., Qin, M. Q., Li, J., Zhu, Y., & Luan, Z. (2015). Similar outcomes of allogeneic hematopoietic cell transplantation from unrelated donor and umbilical cord blood vs. sibling donor for pediatric acute myeloid leukemia: Multicenter experience in China. Pediatric Transplantation, 19(4), 413-21. https://doi.org/10.1111/petr.12475
Tang X, et al. Similar Outcomes of Allogeneic Hematopoietic Cell Transplantation From Unrelated Donor and Umbilical Cord Blood Vs. Sibling Donor for Pediatric Acute Myeloid Leukemia: Multicenter Experience in China. Pediatr Transplant. 2015;19(4):413-21. PubMed PMID: 25903451.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Similar outcomes of allogeneic hematopoietic cell transplantation from unrelated donor and umbilical cord blood vs. sibling donor for pediatric acute myeloid leukemia: Multicenter experience in China. AU - Tang,Xiangfeng, AU - Chen,Jing, AU - Fang,Jianpei, AU - Sun,Xin, AU - Qin,Mao Quan, AU - Li,Junhui, AU - Zhu,Yiping, AU - Luan,Zuo, Y1 - 2015/04/22/ PY - 2015/03/17/accepted PY - 2015/4/24/entrez PY - 2015/4/24/pubmed PY - 2016/4/8/medline KW - bone marrow KW - hematopoietic cell transplantation KW - pediatric acute myeloid leukemia KW - peripheral blood stem cell KW - sibling KW - umbilical cord blood KW - unrelated donor SP - 413 EP - 21 JF - Pediatric transplantation JO - Pediatr Transplant VL - 19 IS - 4 N2 - In a multicenter study, we have conducted a retrospective study on 73 pediatric AML patients who were primary refractory or in greater than CR1 and investigated MSD (or MMSD) (n = 20), URD (n = 23), and UCB (n = 30) HCT between January 1998 and October 2009. The median day to neutrophil engraftment was similar in all groups. The median day to platelet engraftment was longer in the UCB group. The number of HLA mismatch was higher in the UCB group (p = 0.034); however, the cumulative incidence of grade III-IV aGVHD was not different among all groups (p = 0.125); furthermore, cGVHD was lower in the UCB group (p = 0.078). The risk of relapse did not differ among all groups (RR = 1.28, p = 0.125), but the patients of MSD (or MMSD) grafts had a trend of higher risk recurrence. Sixty-two patients survived with a median follow-up of 58.2 months. Five-yr LFS was 73.1%, 59.8%, and 59.6% for URD, UCB, and MSD (or MMDS), respectively (p = 0.426). Five-yr LFS in CR1 was 68.9%, with a significantly better result compared to 41.7% in CR2 (p = 0.025). Our comparisons suggest that pediatric AML patients receiving UCB had a higher early TRM, a lower cGVHD rate, and a similar long-term survival. The outcome of URD and UCB is comparable to that of a suitable sibling for pediatric AML. SN - 1399-3046 UR - https://www.unboundmedicine.com/medline/citation/25903451/Similar_outcomes_of_allogeneic_hematopoietic_cell_transplantation_from_unrelated_donor_and_umbilical_cord_blood_vs__sibling_donor_for_pediatric_acute_myeloid_leukemia:_Multicenter_experience_in_China_ L2 - https://doi.org/10.1111/petr.12475 DB - PRIME DP - Unbound Medicine ER -